The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The
https://
ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.
Learn more:
PMC Disclaimer
Diabetologia.
(2011)
54
:10–8. 10.1007/s00125-010-1896-4 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
4.
Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, Vilsboll T, et al..
Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies
.
Diabetologia.
(2013)
56
:965–72. 10.1007/s00125-013-2841-0
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
5.
Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR.
Human distribution and release of a putative new gut hormone, peptide YY
.
Gastroenterology
. (1985)
89
:1070–7. 10.1016/0016-5085(85)90211-2 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
6.
Vilsboll T, Holst JJ.
Incretins, insulin secretion and Type 2 diabetes mellitus
.
Diabetologia.
(2004)
47
:357–66. 10.1007/s00125-004-1342-6 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
7.
Drucker DJ, Nauck MA.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
.
Lancet.
(2006)
368
:1696–705. 10.1016/S0140-6736(06)69705-5 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
8.
Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, et al..
Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide
.
Diabetes.
(1989)
38
:902–5. 10.2337/diab.38.7.902 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
9.
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W.
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
.
Diabetologia.
(1993)
36
:741–4. 10.1007/BF00401145 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
10.
Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA.
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients
.
J Clin Endocrinol Metab.
(1996)
81
:327–32. 10.1210/jcem.81.1.8550773 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
11.
Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM.
Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men
.
Am J Clin Nutr.
(1998)
68
:525–30. 10.1093/ajcn/68.3.525 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
12.
Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A.
The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
.
Int J Obes Relat Metab Disord.
(2001)
25
:781–92. 10.1038/sj.ijo.0801627 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
13.
Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, et al..
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers
.
J Clin Endocrinol Metab.
(2002)
87
:1239–46. 10.1210/jcem.87.3.8355 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
14.
Holst JJ, Gromada J.
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
.
Am J Physiol Endocrinol Metab.
(2004)
287
:E199–206. 10.1152/ajpendo.00545.2003 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
15.
Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ.
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
.
Diabetes.
(2010)
59
:1765–70. 10.2337/db09-1414
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
16.
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al..
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
.
Am J Physiol.
(1997)
273
(
5 Pt 1
):E981–8. 10.1152/ajpendo.1997.273.5.E981 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
17.
Vilsboll T, Krarup T, Madsbad S, Holst JJ.
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
.
Diabetologia.
(2002)
45
:1111–9. 10.1007/s00125-002-0878-6 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
18.
Mentis N, Vardarli I, Kothe LD, Holst JJ, Deacon CF, Theodorakis M, et al.
GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes
.
Diabetes.
(2011)
60
:1270–6. 10.2337/db10-1332
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
19.
Mentlein R, Gallwitz B, Schmidt WE.
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
.
Eur J Biochem.
(1993)
214
:829–35. 10.1111/j.1432-1033.1993.tb17986.x [
PubMed
] [
CrossRef
]
[
Google Scholar
]
20.
Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA.
Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans
.
J Clin Endocrinol Metab.
(2003)
88
:1772–9. 10.1210/jc.2002-021479 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
21.
Demuth HU, McIntosh CH, Pederson RA.
Type 2 diabetes–therapy with dipeptidyl peptidase IV inhibitors
.
Biochim Biophys Acta.
(2005)
1751
:33–44. 10.1016/j.bbapap.2005.05.010 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
22.
Craddy P, Palin HJ, Johnson KI.
Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison
.
Diabetes Ther.
(2014)
5
:1–41. 10.1007/s13300-014-0061-3
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
23.
Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I.
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
.
Diabetes Metab Res Rev.
(2010)
26
:540–9. 10.1002/dmrr.1114 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
24.
Amori RE, Lau J, Pittas AG.
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis
.
JAMA.
(2007)
298
:194–206. 10.1001/jama.298.2.194 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
25.
Madsbad S.
Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)–preclinical and clinical results
.
Best Pract Res Clin Endocrinol Metab.
(2009)
23
:463–77. 10.1016/j.beem.2009.03.008 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
26.
Gerich J.
DPP-4 inhibitors: what may be the clinical differentiators?
Diabetes Res Clin Pract.
(2010)
90
:131–40. 10.1016/j.diabres.2010.07.006 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
27.
Stonehouse A, Walsh B, Cuddihy R.
Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies
.
Diabetes Technol Ther.
(2011)
13
:1063–9. 10.1089/dia.2011.0076
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
28.
Holst JJ.
The physiology of glucagon-like peptide 1
.
Physiol Rev.
(2007)
87
:1409–39. 10.1152/physrev.00034.2006 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
29.
Meier JJ.
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
.
Nat Rev Endocrinol.
(2012)
8
:728–42. 10.1038/nrendo.2012.140 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
30.
Drucker DJ.
Mechanisms of action and therapeutic application of glucagon-like peptide-1
.
Cell Metab.
(2018)
27
:740–56. 10.1016/j.cmet.2018.03.001 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
31.
Uccellatore A, Genovese S, Dicembrini I, Mannucci E, Ceriello A.
Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists
.
Diabetes Ther.
(2015)
6
:239–56. 10.1007/s13300-015-0127-x
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
32.
Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A.
Glucagon-like peptide analogues for type 2 diabetes mellitus
.
Cochrane Database Syst Rev.
(2011)
10
:CD006423. 10.1002/14651858.CD006423.pub2
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
33.
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, et al..
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
.
Diabetes Care.
(2004)
27
:2628–35. 10.2337/diacare.27.11.2628 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
34.
Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, et al.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
.
Diabetes Obes Metab.
(2007)
9
:733–45. 10.1111/j.1463-1326.2007.00744.x [
PubMed
] [
CrossRef
]
[
Google Scholar
]
35.
Davidson JA.
Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
.
Cleve Clin J Med.
(2009)
76
(
Suppl
)
5
:S28–38. 10.3949/ccjm.76.s5.05 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
36.
Marre M, Shaw J, Brandle M, Bebakar WMW, Kamaruddin NA, Strand J, et al..
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
.
Diabetes Med.
(2009)
26
:268–78. 10.1111/j.1464-5491.2009.02666.x
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
37.
Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al..
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
.
Lancet.
(2010)
375
:2234–43. 10.1016/S0140-6736(10)60406-0 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
38.
Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al..
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
.
J Clin Endocrinol Metab.
(2011)
96
:1301–10. 10.1210/jc.2010-2081 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
39.
Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al..
Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)
.
Diabetes Care.
(2014)
37
:2159–67. 10.2337/dc13-2760 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
40.
Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al..
Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial
.
Diabetes Care.
(2018)
41
:258–66. 10.2337/dc17-0417 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
41.
Pratley RE, Aroda VR, Lingvay I, Ludemann J, Andreassen C, Navarria A, et al..
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
.
Lancet Diabetes Endocrinol.
(2018)
6
:275–86. 10.1016/S2213-8587(18)30024-X [
PubMed
] [
CrossRef
]
[
Google Scholar
]
42.
DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L.
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
.
Curr Med Res Opin.
(2008)
24
:2943–52. 10.1185/03007990802418851 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
43.
Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH.
Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study
.
Diabetes Obes Metab.
(2011)
13
:982–9. 10.1111/j.1463-1326.2011.01428.x
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
44.
Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, et al..
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
.
Lancet.
(2010)
376
:431–9. 10.1016/S0140-6736(10)60590-9 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
45.
Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al.
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
.
Lancet.
(2010)
375
:1447–56. 10.1016/S0140-6736(10)60307-8 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
46.
Van Gaal L, Souhami E, Zhou T, Aronson R.
Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus
.
J Clin Transl Endocrinol.
(2014)
1
:31–7. 10.1016/j.jcte.2014.03.001
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
47.
Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R.
Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial)
.
Diabetes Ther.
(2012).
3
:13. 10.1007/s13300-012-0013-8.
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
48.
Ahren B, Johnson SL, Stewart M, Cirkel DT, Yang F, Perry C, et al..
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin
.
Diabetes Care.
(2014)
37
:2141–8. 10.2337/dc14-0024 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
49.
Leiter LA, Carr MC, Stewart M, Jones-Leone A, Scott R, Yang F, et al..
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study
.
Diabetes Care.
(2014)
37
:2723–30. 10.2337/dc13-2855 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
50.
Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z.
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)
.
Diabetes Care.
(2014)
37
:2149–58. 10.2337/dc13-2761
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
51.
Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z.
Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study
.
Diabetes Obes Metab.
(2015)
17
:849–58. 10.1111/dom.12479
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
52.
Ahren B, Masmiquel L, Kumar H, Sargin M, Karsbol JD, Jacobsen SH, et al..
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
.
Lancet Diabetes Endocrinol.
(2017)
5
:341–54. 10.1016/S2213-8587(17)30092-X [
PubMed
] [
CrossRef
]
[
Google Scholar
]
53.
Seino Y, Min KW, Niemoeller E, Takami A, Investigators EG-LAS.
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
.
Diabetes Obes Metab.
(2012)
14
:910–7. 10.1111/j.1463-1326.2012.01618.x
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
54.
Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al..
Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial
.
JAMA
. (2019)
321
:1466–80. 10.1001/jama.2019.2942
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
55.
Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al..
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
.
J Clin Endocrinol Metab.
(2003)
88
:3082–9. 10.1210/jc.2002-021545 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
56.
Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al..
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses
.
Clin Pharmacol Ther.
(2005)
78
:675–88. 10.1016/j.clpt.2005.09.002 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
57.
Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, et al..
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects
.
Diabetes Care.
(2002)
25
:1398–404. 10.2337/diacare.25.8.1398 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
58.
Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, et al..
Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes
.
J Clin Endocrinol Metab.
(2008)
93
:4810–7. 10.1210/jc.2008-1518 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
59.
Rosenstock J, Reusch J, Bush M, Yang F, Stewart M, Albiglutide Study G.
Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing
.
Diabetes Care.
(2009)
32
:1880–6. 10.2337/dc09-0366
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
60.
Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B.
LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects
.
Diabetes Obes Metab.
(2011)
13
:434–8. 10.1111/j.1463-1326.2011.01365.x [
PubMed
] [
CrossRef
]
[
Google Scholar
]
61.
Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler J, Kofoed J, et al..
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
.
J Med Chem.
(2015)
58
:7370–80. 10.1021/acs.jmedchem.5b00726 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
62.
Philippart M, Schmidt J, Bittner B.
Oral delivery of therapeutic proteins and peptides: an overview of current technologies and recommendations for bridging from approved intravenous or subcutaneous administration to novel oral regimens
.
Drug Res.
(2016)
66
:113–20. 10.1055/s-0035-1559654 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
63.
Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J.
Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial
.
JAMA.
(2017)
318
:1460–70. 10.1001/jama.2017.14752
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
64.
Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, et al..
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
.
Lancet Diabetes Endocrinol.
(2019)
7
:528–39. 10.1016/S2213-8587(19)30194-9 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
65.
Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al..
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes
.
Diabetes.
(2004)
53
:1187–94. 10.2337/diabetes.53.5.1187 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
66.
Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, et al..
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
.
Diabetes Care.
(2006)
29
:2632–7. 10.2337/dc06-0703 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
67.
McGill JB.
Insights from the liraglutide clinical development program–the liraglutide effect and action in diabetes (LEAD) studies
.
Postgrad Med.
(2009)
121
:16–25. 10.3810/pgm.2009.05.1998 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
68.
Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, et al.
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
.
Diabet Med.
(2011)
28
:705–14. 10.1111/j.1464-5491.2011.03301.x
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
69.
Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, et al..
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial
.
Diabetes Care.
(2012)
35
:1986–93. 10.2337/dc11-2113
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
70.
Bailey TS, Takacs R, Tinahones FJ, Rao PV, Tsoukas GM, Thomsen AB, et al..
Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial
.
Diabetes Obes Metab.
(2016)
18
:1191–8. 10.1111/dom.12736
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
71.
Violante R, Oliveira JH, Yoon KH, Reed VA, Yu MB, Bachmann OP, et al..
A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin
.
Diabet Med.
(2012).
29
:e417–24. 10.1111/j.1464-5491.2012.03624.x. [
PubMed
] [
CrossRef
]
[
Google Scholar
]
72.
Nauck MA, Kahle M, Baranov O, Deacon CF, Holst JJ.
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes
.
Diabetes Obes Metab.
(2017).
19
:200–207. 10.1111/dom.12802. [
PubMed
] [
CrossRef
]
[
Google Scholar
]
73.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al..
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
.
N Engl J Med.
(2013)
369
:1317–26. 10.1056/NEJMoa1307684 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
74.
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al..
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
.
N Engl J Med.
(2013)
369
:1327–35. 10.1056/NEJMoa1305889 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
75.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al..
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
.
N Engl J Med.
(2015)
373
:232–42. 10.1056/NEJMoa1501352 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
76.
Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, et al..
Cardiovascular outcomes trials in type 2 diabetes: where do we go from here?
Reflections From a Diabetes Care Editors' Expert Forum.
Diabetes Care.
(2018)
41
:14–31. 10.2337/dci17-0057
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
77.
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al..
Lixisenatide in patients with type 2 diabetes and acute Coronary syndrome
.
N Engl J Med.
(2015)
373
:2247–57. 10.1056/NEJMoa1509225 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
78.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al..
Liraglutide and cardiovascular outcomes in type 2 diabetes
.
N Engl J Med.
(2016)
375
:311–22. 10.1056/NEJMoa1603827
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
79.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al..
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
.
N Engl J Med.
(2016)
375
:1834–44. 10.1056/NEJMoa1607141 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
80.
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al..
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
.
N Engl J Med.
(2017)
377
:1228–39. 10.1056/NEJMoa1612917
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
81.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al..
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
.
Lancet.
(2019)
394
:121–30. 10.1016/S0140-6736(19)31149-3 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
82.
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al..
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
.
N Engl J Med.
(2019)
381
:841–51. 10.1056/NEJMoa1901118 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
83.
Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, et al..
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
.
BMJ.
(2016)
353
:i2231. 10.1136/bmj.i2231
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
84.
Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA.
Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
.
Diabetes Obes Metab.
(2011)
13
:258–67. 10.1111/j.1463-1326.2010.01350.x [
PubMed
] [
CrossRef
]
[
Google Scholar
]
85.
Goossen K, Graber S.
Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis
.
Diabetes Obes Metab.
(2012)
14
:1061–72. 10.1111/j.1463-1326.2012.01610.x [
PubMed
] [
CrossRef
]
[
Google Scholar
]
86.
Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study G.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
.
Diabetes Care.
(2006)
29
:2638–43. 10.2337/dc06-0706 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
87.
Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H, et al..
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
.
Diabetologia.
(2006)
49
:2564–71. 10.1007/s00125-006-0416-z [
PubMed
] [
CrossRef
]
[
Google Scholar
]
88.
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study G.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
.
Clin Ther.
(2006)
28
:1556–68. 10.1016/j.clinthera.2006.10.007 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
89.
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ.
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
.
Diabetes Care.
(2007)
30
:890–5. 10.2337/dc06-1732 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
90.
Brunton S.
GLP-1 receptor agonists vs
. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
Int J Clin Pract.
(2014)
68
:557–67. 10.1111/ijcp.12361
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
91.
Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, et al..
Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
.
BMJ.
(2018)
360
:k872. 10.1136/bmj.k872
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
92.
Chaicha-Brom T, Yasmeen T.
DPP-IV inhibitor-associated arthralgias
.
Endocr Pract.
(2013)
19
:377. 10.4158/EP13076.LT [
PubMed
] [
CrossRef
]
[
Google Scholar
]
93.
Tarapues M, Cereza G, Figueras A.
Association of musculoskeletal complaints and gliptin use: review of spontaneous reports
.
Pharmacoepidemiol Drug Saf.
(2013)
22
:1115–8. 10.1002/pds.3503 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
94.
Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD.
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes
.
Diabetes Metab Res Rev.
(2004)
20
:411–7. 10.1002/dmrr.499 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
95.
Rosenstock J, Fonseca VA, Gross JL, Ratner RE, Ahren B, Chow FC, et al..
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro
.
Diabetes Care.
(2014)
37
:2317–25. 10.2337/dc14-0001 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
96.
Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al..
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
.
N Engl J Med.
(2014)
370
:794–7. 10.1056/NEJMp1314078 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
98.
Lopez-Ruiz A, del Peso-Gilsanz C, Meoro-Aviles A, Soriano-Palao J, Andreu A, Cabezuelo J, et al..
Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers
.
Pharm World Sci.
(2010)
32
:559–61. 10.1007/s11096-010-9423-8 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
99.
Kaakeh Y, Kanjee S, Boone K, Sutton J.
Liraglutide-induced acute kidney injury
.
Pharmacotherapy.
(2012)
32
:e7–11. 10.1002/PHAR.1014 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
100.
Nandakoban H, Furlong TJ, Flack JR.
Acute tubulointerstitial nephritis following treatment with exenatide
.
Diabet Med.
(2013)
30
:123–5. 10.1111/j.1464-5491.2012.03738.x [
PubMed
] [
CrossRef
]
[
Google Scholar
]
101.
Leibovitz E, Gottlieb S, Goldenberg I, Gevrielov-Yusim N, Matetzky S, Gavish D.
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)
.
Cardiovasc Diabetol.
(2013)
12
:53. 10.1186/1475-2840-12-53
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
102.
Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al..
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes
.
Diabetes Care.
(2011)
34
:1481–6. 10.2337/dc10-2415
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
103.
Nicolucci A, Cucinotta D, Squatrito S, Lapolla A, Musacchio N, Leotta S, et al..
Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes
.
Nutr Metab Cardiovasc Dis.
(2009)
19
:45–53. 10.1016/j.numecd.2007.12.005 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
104.
Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al..
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
.
Int J Clin Pract.
(2011)
65
:397–407. 10.1111/j.1742-1241.2011.02656.x
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
Articles from
Frontiers in Endocrinology
are provided here courtesy of
Frontiers Media SA
